NTRK1 and cancer: The portability of the PROTABs platform was further assessed by exploring degradation of HER2, PD-L1 and FZD5, three therapeutically relevant cancer targets encompassing membrane receptors of various families (receptor tyrosine kinases, immunoglobulins and G-protein-coupled receptors, respectively).